Integrative evaluation of primary and metastatic lesion spectrum to guide anti-PD-L1 therapy of non-small cell lung cancer: results from two randomized studies

Benzer Materyaller

• Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice
  Yazar:: Si-Cong Ma, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-04-01)
• The expression of PD-1 and LAG-3 in periapical lesions
  Yazar:: Wang, Hai-Sheng, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma
  Yazar:: Ma, Si-Cong, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Variable density of CD8+ and CD25+ programmed cell death-1 (PD-1) ligand (PD-L1) CD4+ T cells within the tumor microenvironment causes differential responses to the PD-1/PD-L1 blockade
  Yazar:: Wu, Si-Pei, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Efficacy of Anti-PD-1/PD-L1 Monotherapy or Combinational Therapy in Patients Aged 75 Years or Older: A Study-Level Meta-Analysis
  Yazar:: Nie, Run-Cong, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)